Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503350 | 0.89 | MAPT (0.39) | KLKB1HSD17B10POLBL3MBTL1ALDH1A1 | |
| SCHEMBL30057390 | 0.89 | MAPT (0.39) | KLKB1HSD17B10POLBL3MBTL1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL21492529 | 0.86 | KLKB1 (0.39) | KLKB1POLBBRD4ALDH1A1KLK1 | |
| Trifluoroacetic Acid SCHEMBL28523073 | 0.82 | SCD5 (0.42) | SCD5SCDALDH1A1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL21492824 | 0.79 | DPP4 (0.37) | KLKB1BRD4KLK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21491678 | 0.76 | KLKB1 (0.39) | KLKB1 | |
| Trifluoroacetic Acid SCHEMBL21491995 | 0.74 | CPB1 (0.37) | KLKB1HSD17B10BRD4ALDH1A1KDM4E | |
| SCHEMBL21503615 | 0.74 | GABRA1 (0.37) | KLKB1POLBALDH1A1KLK1 | |
| Trifluoroacetic Acid SCHEMBL21491685 | 0.73 | HSD17B10 (0.38) | KLKB1HSD17B10POLBL3MBTL1TDP1 | |
| Trifluoroacetic Acid SCHEMBL21491813 | 0.73 | L3MBTL1 (0.46) | KLKB1HSD17B10POLBL3MBTL1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KLKB1 630/4885HSD17B10 1245/4885POLB 300/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | KLKB1 630/4885HSD17B10 1245/4885POLB 300/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KLKB1 630/4885HSD17B10 1245/4885POLB 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.